Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Urolithin A is a gut microbiome-derived metabolite of ellagitannins, compounds found in foods like pomegranates, berries, and walnuts. Its use for Alzheimer's Disease (AD) is based on emerging scientific evidence, mostly from preclinical research, rather than traditional use. Recent studies suggest that Urolithin A may improve mitochondrial health, reduce neuroinflammation, and modulate autophagy, all of which are implicated in the pathology of AD. For example, animal models of Alzheimer's have shown that Urolithin A administration can reduce amyloid-beta plaque accumulation and improve cognitive function, largely attributed to enhanced mitophagy (the selective degradation of damaged mitochondria).

However, human clinical trials specifically examining Urolithin A in Alzheimer's patients are lacking as of mid-2024. The available human data focus on safety, bioavailability, and its effects on muscle and mitochondrial health in older adults, not on cognitive outcomes or AD biomarkers. Thus, while mechanistic and animal studies provide a scientific rationale, the evidence for Urolithin A's efficacy in Alzheimer's Disease remains preliminary and indirect. More robust clinical trials are needed to confirm its benefits and safety for this indication.

More about Urolithin A
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by Urolithin A

Products containing Urolithin A

Pure Encapsulations Renual